Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains
Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.
Pharma & Biotech
Pharma & Biotech
Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Medical Devices & Diagnostics
Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial
Corcept's MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.
Pharma & Biotech
Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.